• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-3MEF filed by ASP Isotopes Inc.

    7/23/25 4:53:34 PM ET
    $ASPI
    Major Chemicals
    Industrials
    Get the next $ASPI alert in real time by email
    S-3MEF 1 aspi_s3mef.htm S-3MEF aspi_s3mef.htm

    As filed with the Securities and Exchange Commission on July 23, 2025

    Registration No. 333-            

     

    UNITED STATES 

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-3

     

    REGISTRATION STATEMENT 

    UNDER

    THE SECURITIES ACT OF 1933

     

    ASP Isotopes Inc.

    (Exact name of registrant as specified in its charter)

     

    Delaware

    87-2618235

    (State or other jurisdiction of

     

    (I.R.S. Employer

    incorporation or organization)

     

    Identification Number)

     

    601 Pennsylvania Avenue NW

    South Building, Suite 900 

    Washington, D.C. 20004

    (202) 756-2245

    (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

     

    Paul E. Mann 

    Executive Chairman and Chief Executive Officer

    ASP Isotopes Inc.

    601 Pennsylvania Avenue NW

    South Building, Suite 900

    Washington, D.C. 20004

    (202) 756-2245

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

    Copy to:

    Donald G. Ainscow, Esq.

    Blank Rome LLP

    200 Crescent Court, Suite 1000

    Dallas, TX 75201

    Tel: (972) 850-1450

    Fax: (972) 850-1451

     

    Approximate date of commencement of proposed sale to the public: From time to time after the effective date of this registration statement.

     

    If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box: ☐

     

    If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box: ☒

     

    If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering: ☒ 333-286860

     

    If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

     

    If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. ☐

     

    If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box. ☐

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer

    ☐

    Accelerated filer

    ☐ 

    Non-accelerated filer

    ☒ 

    Smaller reporting company

    ☒ 

     

     

    Emerging growth company

    ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

    This registration statement shall become effective upon filing in accordance with Rule 462(b) promulgated under the Securities Act of 1933, as amended.

     

     

     

     

    EXPLANATORY NOTE

    AND INCORPORATION OF CERTAIN INFORMATION BY REFERENCE

     

    Pursuant to Rule 462(b) under the Securities Act of 1933, as amended, ASP Isotopes Inc. (the “Registrant”) is filing this Registration Statement on Form S-3 (this “Registration Statement”) with the Securities and Exchange Commission (the “Commission”). This Registration Statement relates to the public offering of securities contemplated by the Registration Statement on Form S-3 (File No. 333-286860) (the “Prior Registration Statement”), which the Registrant originally filed with the Commission on April 30, 2025, and which the Commission declared effective on May 30, 2025.

     

    The Registrant is filing this Registration Statement for the sole purpose of increasing the aggregate number of securities offered by the Registrant by a proposed aggregate offering price of $10,000,000. The additional securities that are being registered for issuance and sale represent no more than 20% of the maximum aggregate offering price of unsold securities under the Prior Registration Statement. The information set forth in the Prior Registration Statement and all exhibits to the Prior Registration Statement are hereby incorporated by reference into this Registration Statement.  The required opinion and consents are listed on the Exhibit Index below and filed herewith.

     

     
    2

     

     

    PART II

    INFORMATION NOT REQUIRED IN PROSPECTUS

     

    Item 16. Exhibits.

     

    (a) Exhibit Index

     

    All exhibits filed with or incorporated by reference in the Prior Registration Statement are incorporated by reference into, and shall be deemed a part of, this Registration Statement, and the following additional exhibits are filed or incorporated by reference herewith, as part of this Registration Statement:

     

    Exhibit Number

     

    Description 

     

     

    5.1

     

    Opinion of Blank Rome LLP.

    23.1

     

    Consent of Independent Registered Public Accounting Firm.

    23.2

     

    Consent of BDO South Africa Incorporated

    23.3

     

    Consent of Blank Rome LLP (included in Exhibit 5.1).

    24.1

     

    Power of Attorney (incorporated by reference to Exhibit 24.1 to the Prior Registration Statement).

    107

     

    Filing Fee Table.

     

     
    3

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Washington, D.C. on July 23, 2025.

     

     

    ASP ISOTOPES INC.

     

     

     

     

     

    By

    /s/ Paul E. Mann

     

     

     

    Paul E. Mann

    Executive Chairman and Chief Executive Officer

     

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature

     

    Title

     

    Date

     

     

     

     

     

    /s/ Paul E. Mann

     

    Executive Chairman, Chief Executive Officer and Director

    (Principal Executive Officer)

     

    July 23, 2025

    Paul E. Mann

     

     

     

     

     

     

     

    /s/ Heather Kiessling

     

    Chief Financial Officer

    (Principal Financial and Accounting Officer)

     

    July 23, 2025

    Heather Kiessling

     

     

     

     

     

     

     

    *

     

    Director

     

    July 23, 2025

    Michael Gorley, Ph.D.

     

     

     

     

     

     

     

    *

     

    Director

     

    July 23, 2025

    Sipho N. Maseko

     

     

     

     

     

     

     

    *

     

    Director

     

    July 23, 2025

    Duncan Moore, Ph.D.

     

     

     

     

     

     

     

    *

     

    Director

     

    July 23, 2025

    Robert Ryan

     

     

     

     

     

     

     

    *

     

    Director

     

    July 23, 2025

    Todd Wider, M.D.

     

     

     

    * By: 

    /s/ Paul E. Mann

     

    Paul E. Mann

     

     

    Attorney-in-Fact

     

     

     
    4

     

    Get the next $ASPI alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $ASPI

    DatePrice TargetRatingAnalyst
    10/4/2024$4.50Buy
    Canaccord Genuity
    12/5/2023$3.25Buy
    H.C. Wainwright
    More analyst ratings

    $ASPI
    SEC Filings

    See more
    • ASP Isotopes Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - ASP Isotopes Inc. (0001921865) (Filer)

      7/25/25 9:24:44 AM ET
      $ASPI
      Major Chemicals
      Industrials
    • ASP Isotopes Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

      8-K - ASP Isotopes Inc. (0001921865) (Filer)

      7/24/25 7:38:00 AM ET
      $ASPI
      Major Chemicals
      Industrials
    • SEC Form 424B5 filed by ASP Isotopes Inc.

      424B5 - ASP Isotopes Inc. (0001921865) (Filer)

      7/24/25 7:27:49 AM ET
      $ASPI
      Major Chemicals
      Industrials

    $ASPI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Competition Commission of South Africa Approves the Offer by ASP Isotopes Inc. for Renergen Limited

      WASHINGTON, D.C., July 25, 2025 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. NASDAQ: ASPI ("ASP Isotopes" or the "Company"), an advanced materials company dedicated to the development of technology and processes for the production of isotopes for use in multiple industries, today announced that the Company's proposed offer to acquire all of the issued ordinary shares of JSE-listed Renergen Limited ("Renergen") has been approved as of July 23, 2025, by the Competition Commission of South Africa, subject to certain conditions, which are acceptable to the Company. The implementation of the Scheme remains subject to and will only become operative upon the fulfilment or, if applicable, waiver of the

      7/25/25 8:59:48 AM ET
      $ASPI
      Major Chemicals
      Industrials
    • ASP Isotopes Inc. Announces Pricing of $60 Million Underwritten Registered Direct Offering of Common Stock

      WASHINGTON, July 23, 2025 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. NASDAQ: ASPI ("ASP Isotopes" or the "Company"), today announced the pricing of an underwritten registered direct offering of 7,500,000 shares of its common stock at a price of $8.00 per share to a single fundamental institutional investor. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $60.0 million. The offering is expected to close on or about July 25, 2025, subject to the satisfaction of customary closing conditions. Cantor and Canaccord Genuity acted as joint book-running managers for the offering. Ocean Wall Limited a

      7/23/25 6:15:25 PM ET
      $ASPI
      Major Chemicals
      Industrials
    • ASP Isotopes Inc. Announces Updates on the Progress of Commercial Production at its Three Enrichment Facilities in South Africa

      WASHINGTON, July 17, 2025 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. NASDAQ: ASPI ("ASP Isotopes" or the "Company"), an advanced materials company dedicated to the development of technology and processes for the production of isotopes for use in multiple industries, today announced several updates on the progress of commercial production at the Company's three isotope enrichment facilities in Pretoria, South Africa as well as other corporate matters, in advance of a presentation by the Company's Chairman and CEO, Paul Mann, at the Emerging Growth Conference at 10:15 a.m. EST on July 17, 2025. Silicon-28. The Company commenced commercial production of Silicon-28 during late March 2025 and has

      7/17/25 8:00:00 AM ET
      $ASPI
      Major Chemicals
      Industrials

    $ASPI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Canaccord Genuity initiated coverage on ASP Isotopes with a new price target

      Canaccord Genuity initiated coverage of ASP Isotopes with a rating of Buy and set a new price target of $4.50

      10/4/24 7:13:36 AM ET
      $ASPI
      Major Chemicals
      Industrials
    • H.C. Wainwright initiated coverage on ASP Isotopes with a new price target

      H.C. Wainwright initiated coverage of ASP Isotopes with a rating of Buy and set a new price target of $3.25

      12/5/23 7:36:42 AM ET
      $ASPI
      Major Chemicals
      Industrials

    $ASPI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Operating Officer Ainscow Robert sold $1,121,347 worth of shares (200,000 units at $5.61), decreasing direct ownership by 12% to 1,419,992 units (SEC Form 4)

      4 - ASP Isotopes Inc. (0001921865) (Issuer)

      4/17/25 7:57:41 PM ET
      $ASPI
      Major Chemicals
      Industrials
    • Chief Executive Officer Mann Paul Elliot sold $5,326,397 worth of shares (950,000 units at $5.61), decreasing direct ownership by 11% to 7,315,454 units (SEC Form 4)

      4 - ASP Isotopes Inc. (0001921865) (Issuer)

      4/17/25 7:57:18 PM ET
      $ASPI
      Major Chemicals
      Industrials
    • Chief Operating Officer Ainscow Robert was granted 400,000 shares, increasing direct ownership by 33% to 1,619,992 units (SEC Form 4)

      4 - ASP Isotopes Inc. (0001921865) (Issuer)

      4/15/25 8:42:42 AM ET
      $ASPI
      Major Chemicals
      Industrials

    $ASPI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Operating Officer Ainscow Robert bought 19,992 shares, increasing direct ownership by 2% to 919,992 units (SEC Form 4)

      4 - ASP Isotopes Inc. (0001921865) (Issuer)

      7/15/24 10:33:49 AM ET
      $ASPI
      Major Chemicals
      Industrials
    • Chief Executive Officer Mann Paul Elliot bought 39,984 shares, increasing direct ownership by 0.69% to 5,845,627 units (SEC Form 4)

      4 - ASP Isotopes Inc. (0001921865) (Issuer)

      7/15/24 10:33:33 AM ET
      $ASPI
      Major Chemicals
      Industrials
    • Large owner Ak Jensen Investment Management Ltd bought $515,088 worth of shares (161,849 units at $3.18) (SEC Form 4)

      4 - ASP Isotopes Inc. (0001921865) (Issuer)

      7/10/24 5:59:47 PM ET
      $ASPI
      Major Chemicals
      Industrials

    $ASPI
    Leadership Updates

    Live Leadership Updates

    See more
    • Renergen's Phase 2 EPC Contractor Awarded Preferred Bidder Status

      JOHANNESBURG, June 18, 2025 (GLOBE NEWSWIRE) -- Renergen is pleased to announce that preferred bidder status has been awarded to He4u consortium for the design, procurement, delivery, construction and commissioning for phase 2 of the Tetra4 LNG and helium liquefaction project, comprising of, Chart Industries Inc. (NYSE:GTLS), Wilson Bayly Holmes - Ovcon Ltd (JSE: WBO), and Aurex Constructors. The appointment of an acceptable EPC contractor in Phase 2 was one of the two remaining conditions for the DFC Phase 2 loan. The award is a key milestone in the project's progress. The award confirms that Chart Industries' Helium liquefier and LNG liquefaction technologies have been selected as Tet

      6/18/25 10:11:04 AM ET
      $ASPI
      $GTLS
      Major Chemicals
      Industrials
      Metal Fabrications
    • ASP Isotopes Inc. Enhances the Quantum Leap Energy LLC (QLE) Executive Leadership Team with the Appointment of Ryno Pretorius as Chief Executive Officer of QLE

      WASHINGTON , June 11, 2025 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. NASDAQ: ASPI ("ASP Isotopes" or the "Company"), an advanced materials company dedicated to the development of technology and processes for the production of isotopes for use in multiple industries, today announced the appointment of Dr. Ryno Pretorius, PhD as Chief Executive Officer of Quantum Leap Energy LLC (QLE), the Company's subsidiary that is pursuing an initiative to develop and commercialize advanced nuclear fuels, such as High Assay Low-Enriched Uranium (HALEU) and Lithium-6. Dr. Pretorius has previously served as a consultant to both ASP Isotopes and QLE. Paul Mann will continue to serve as the chairman and C

      6/11/25 8:23:05 AM ET
      $ASPI
      Major Chemicals
      Industrials
    • ASP Isotopes Inc. Enhances Executive Leadership Team with the Appointment of Heather Kiessling as Chief Financial Officer

      WASHINGTON, June 13, 2024 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. NASDAQ: ASPI ("ASP Isotopes" or the "Company"), an advanced materials company dedicated to the development of technology and processes for the production of isotopes for use in multiple industries, today announced the appointment of Heather Kiessling as its chief financial officer (CFO), effective as of July 1, 2024 (or such earlier date as may be mutually agreed), to support the Company's next pivotal phase of growth. Robert Ainscow, who currently serves as the Company's CFO and chief operating officer (COO), will continue to serve as the Company's COO, enabling him to focus his full time and attention on the Company's operat

      6/13/24 10:56:52 AM ET
      $ASPI
      Major Chemicals
      Industrials

    $ASPI
    Financials

    Live finance-specific insights

    See more
    • Mobilicom and ASP Isotopes Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

      ORLANDO, FL / ACCESSWIRE / September 13, 2024 / RedChip Companies will air interviews with Mobilicom Ltd. (NASDAQ:MOB) and ASP Isotopes Inc. (NASDAQ:ASPI) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, September 14, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Mobilicom: https://www.redchip.com/assets/access/mob_accessASP Isotopes: https://www.redchip.com/assets/access/aspi_accessOren Elkayam, Founder and CEO of Mobilicom, appears on the RedChip Small Stocks, Big Money™ show on Bloomberg TV to provide a corporate update. Mobilicom presents a

      9/13/24 9:00:00 AM ET
      $ASPI
      $BOXL
      $MOB
      Major Chemicals
      Industrials
      Other Consumer Services
      Real Estate
    • ASP Isotopes and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

      ORLANDO, FL / ACCESSWIRE / May 24, 2024 / RedChip Companies will air interviews with ASP Isotopes Inc. (NASDAQ:ASPI) and Calidi Biotherapeutics Inc. (NYSE:CLDI) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, May 25, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:ASP Isotopes: https://www.redchip.com/assets/access/aspi_accessCalidi Biotherapeutics: https://www.redchip.com/assets/access/cldi_accessIn an exclusive interview, Paul Mann, CEO of ASP Isotopes, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to provide a corporate u

      5/24/24 9:00:00 AM ET
      $ASPI
      $CLDI
      Major Chemicals
      Industrials
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • INNO Holdings and ASP Isotopes Interviews to Air on the RedChip Small Stocks Big Money(R) Show on Bloomberg TV

      ORLANDO, FL / ACCESSWIRE / January 19, 2024 / RedChip Companies will air interviews with INNO Holdings, Inc. (NASDAQ:INHD) and ASP Isotopes, Inc. (NASDAQ:ASPI) on The RedChip Small Stocks Big Money® Show, a sponsored program on Bloomberg TV, this Saturday, January 20, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:INNO Holdings: https://www.redchip.com/assets/access/inhd_accessASP Isotopes: https://www.redchip.com/assets/access/aspi_accessIn an exclusive interview, Alice Gong, COO of INNO Holdings, appears on the RedChip Small Stocks Big Money® Show on Bloomberg TV to provide a corporate update

      1/19/24 1:10:00 PM ET
      $ASPI
      Major Chemicals
      Industrials

    $ASPI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by ASP Isotopes Inc.

      SC 13G - ASP Isotopes Inc. (0001921865) (Subject)

      11/14/24 3:01:19 PM ET
      $ASPI
      Major Chemicals
      Industrials
    • Amendment: SEC Form SC 13G/A filed by ASP Isotopes Inc.

      SC 13G/A - ASP Isotopes Inc. (0001921865) (Subject)

      11/7/24 4:15:14 PM ET
      $ASPI
      Major Chemicals
      Industrials
    • SEC Form SC 13G filed by ASP Isotopes Inc.

      SC 13G - ASP Isotopes Inc. (0001921865) (Subject)

      11/3/23 4:15:20 PM ET
      $ASPI
      Major Chemicals
      Industrials